Frankfurt/Main – Bruker Corporation, a NASDAQ-listed US tech company, has entered into a partnership with Swiss firm Biognosys AG to deliver advanced proteomics CRO services for US biopharma and biomarker customers. As part of the partnership, Bruker has made a majority-ownership investment in Biognosys AG. Biognosys is a leader in the development of proteomics technologies and solutions for pharmaceutical and biotech research. The strategic partnership is expected to create unique synergies between Biognosys’ portfolio of proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. As a result of the partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the US. Details of the transaction were not disclosed.
An international CMS team headed by Dr Hendrik Hirsch and Stefan Brunnschweiler advised Bruker on all legal aspects of the transaction. Bruker has also relied on the expertise of CMS in the past. Previous work by CMS for Bruker Corporation included providing legal advice on the company’s investment in PreOmics.
CMS Germany
Dr Hendrik Hirsch, Lead Partner, Frankfurt/Main
Dr Berrit Roth-Mingram, Senior Associate, Frankfurt/Main, both Corporate/M&A
Dr Thomas Hirse, Partner, Düsseldorf
Sven Krause, Senior Associate, Düsseldorf, both Intellectual Property
CMS Switzerland
Stefan Brunnschweiler, Lead Partner
Press Contact
presse@cms-hs.com
